

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,884,434
Title: TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A D2 AGONIST AND WHICH IS PROVIDED FOR TREATING PARKINSONISM, AND A METHOD FOR THE PRODUCTION THEREOF
Issue Date: 26 April 2005
Inventors: Walter Mueller and James V. Peck
Assignees & Owners: LTS Lohmann Therapie-Systeme AG and Schwarz Pharma Limited

SUBMITTED ELECTRONICALLY VIA EFS-WEB

30 November 2010

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Mary Till, Esq.

LETTER REGARDING USPTO DETERMINATION OF NEW PATENT EXPIRATION

DATE

This paper is in response to the "Notice of Final Determination" mailed 1 Nov 2010 ("Notice"). The Notice states that U.S. Patent No. 6,884,434 ("U.S.'434") is eligible for a Patent Term Extension ("PTE") of 743 days. The original expiration date of U.S.'434 is 18 March 2019. The Notice states that the new expiration date (including PTE term) is 26 April 2022. However, Applicant submits that the new expiration date is 30 March 2021, which is 743 days after the original expiration date, 18 March 2019. Applicant requests clarification.

Respectfully submitted,
HARNESS, DICKEY & PIERCE, P.L.C.

/ Leanne M. Rakers /

Leanne M. Rakers
Attorney for Applicant
Reg. No. 64,412
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
314.726.7514 (direct)
314.726.7501 (fax)